Anvisa prohibits advertising of Semavy slimming pen
The agency's determination occurred after non-compliance with health legislation.
TL;DR
- Anvisa has suspended all advertising for the slimming pen Semavy.
- The suspension is due to the product's classification (red or black label) which restricts its advertising.
- Brazilian health legislation prohibits the advertising of prescription medications in mass media channels.
- Semavy's advertisements were found to be in unauthorized channels.
- Slimming pens, like Semavy, are indicated for type 2 diabetes and obesity control under medical supervision.
- Sale of these medications requires a prescription, and self-medication can cause adverse effects.
- Anvisa encourages consumers to check the regularity of medications through its portal.